Matthew Meriggioli to Double-Blind Method
This is a "connection" page, showing publications Matthew Meriggioli has written about Double-Blind Method.
Connection Strength
0.186
-
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. J Clin Neurosci. 2024 Jan; 119:76-84.
Score: 0.051
-
Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
Score: 0.050
-
Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 2003 Sep-Oct; 20(5):382-5.
Score: 0.050
-
Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
Score: 0.036